A classification method based on principal components of SELDI spectra to diagnose of lung adenocarcinoma

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Lin, Qiang ^a   Peng, Qianqian ^b   Yao, Feng ^a   Pan, Xu Feng ^a   Xiong, Li Wen ^a   Wang, Yi ^b   Geng, Jun Feng ^a   Feng, Jiu Xian ^a   Han, Bao Hui ^a   Bao, Guo Liang ^a   Yang, Yu ^a   Wang, Xiaotian ^b   Jin, Li ^b   Guo, Wensheng ^c   Wang, Jiu Cun ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CONTROLLED STUDY; DECISION TREE; DISCRIMINANT ANALYSIS; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PERFORMANCE MEASUREMENT SYSTEM; PRINCIPAL COMPONENT ANALYSIS; REPRODUCIBILITY; SUPPORT VECTOR MACHINE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION STUDY; ADENOCARCINOMA; CLASSIFICATION; LUNG TUMOR; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MIDDLE AGED; PROTEOMICS; STATISTICAL MODEL;

ADENOCARCINOMA; ADULT; AGED; FEASIBILITY STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84858820763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034457     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Ministry of Health of the People's Republic of China (2003) Layout and compendium of the prevention and control of cancer in China (2004-2010).
3. Beadsmoore CJ, Screaton NJ, (2003) Classification, staging and prognosis of lung cancer. Eur J Radiol 45: 8-17.
4. Ginsberg RJ, Vokes EE, Raben A, (1997) Non-small cell lung cancer Philadelphia JB Lippincott.
5. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
6. Cho WC, Cheng CH, (2007) Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics 4: 401-410.
7. Cho WC, (2007) Proteomics technologies and challenges. Genomics Proteomics Bioinformatics 5: 77-85.
8. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA, (2002) Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1: 683-695.
9. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 8: 2541-2552.
10. Conrad DH, Goyette J, Thomas PS, (2008) Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med Suppl 1: 78-84.
11. Granville CA, Dennis PA, (2005) An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32: 169-176.
12. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, et al. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-3614.
13. Yaping C, (2009) Analysis of SELDI mass spectra for biomarker discovery and cancer classification Birmingham University of Birmingham.
14. Lysek M, Persson T, (2005) Diagnostics using SELDI-TOF Mass Spectrometry Sweden Halmstad University.
15. Caffrey RE, (2010) A review of experimental design best practices for proteomics based biomarker discovery: focus on SELDI-TOF. Methods Mol Biol 641: 167-183.
16. Hong YJ, Wang XD, Shen D, Zeng S, (2008) Discrimination analysis of mass spectrometry proteomics for ovarian cancer detection. Acta Pharmacol Sin 29: 1240-1246.
17. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, et al. (2004) Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 6: 674-686.
18. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, et al. (2004) Serum diagnosis of pancreatic adenocarcinoma using surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 10: 860-868.
19. Sreseli RT, Binder H, Kuhn M, Digel W, Veelken H, et al. (2010) Identification of a 17-protein signature in the serum of lung cancer patients. Oncol Rep 24: 263-270.
20. Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, et al. (2005) Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5: 83.
21. Han KQ, Huang G, Gao CF, Wang XL, Ma B, et al. (2008) Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 31: 133-139.
22. Au JS, Cho WC, Yip TT, Yip C, Zhu H, et al. (2007) Deep proteome profiling of sera from never-smoked lung cancer patients. Biomed Pharmacother 61: 570-577.
23. Albrethsen J, (2007) Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 53: 852-858.
24. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, et al. (2002) AJCC Cancer Staging Manual New York Springer pp. 167-181.
25. Cattell RB, (1966) The scree test for the number of factors. Multivariate Behavioral Research 1: 245-276.
26. Browne MW, (1968) A comparison of factor analytic techniques. Psychometrika 33: 267-334.
27. Hosmer DW, Lemeshow S, (2000) Applied Logistic Regression NY John Wiley & Sons.
28. Nilsen MM, Meier S, Andersen OK, Hjelle A, (2011) SELDI-TOF MS analysis of alkylphenol exposed Atlantic cod with phenotypic variation in gonadosomatic index. Mar Pollut Bull 62: 2507-2511.
29. Lilien RH, Farid H, Donald BR, (2003) Probabilistic disease classification of expression-dependent proteomic data from mass spectrometry of human serum. J Comput Biol 10: 925-946.
30. Liu Z, Chen D, Bensmail H, (2005) Gene Expression Data ClassificationWith Kernel Principal Component Analysis. J Biomed Biotechnol 2005: 155-159.
31. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, et al. (2005) Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41: 40-47.
32. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
33. Cho WC, (2006) [Research progress in SELDI-TOF MS and its clinical applications]. Sheng Wu Gong Cheng Xue Bao 22: 871-876.
34. Reed MF, Molloy M, Dalton EL, Howington JA, (2004) Survival after resection for lung cancer is the outcome that matters. Am J Surg 188: 598-602.
35. Kristina G, Radomir P, Eva B, Lenka D, Radek L, et al. (2009) When one chip is not enough: augmenting the validity of SELDI-TOF proteomic profiles of clinical specimens. Lab Chip 9: 1014-1017.